anonymous
Guest
anonymous
Guest
To keep things simple, the “bottom line,” so to speak, will be Michel discussing cost savings. These cost savings make Biogen’s earnings call not look as gruesome as they will be discussing making more money in other endeavors in the future by spending less. Michel, as CEO, makes the final decision but he has been promising investors more $ cuts if this decision happens. Inevitably they would like to have this done prior to the earnings call rather than have all these employees on the books $$$ where it is an obvious lost cause. Lec is too far off to justify carrying employees in addition that Biogen doesn't own that drug.